Overview

A Multiple Ascending Dose Study of COR388

Status:
Completed
Trial end date:
2018-10-15
Target enrollment:
Participant gender:
Summary
The study is a randomized, double-blind, placebo-controlled, multiple ascending dose study to assess the safety and tolerability of ascending repeat doses of COR388 HCl in older healthy male and female subjects and a cohort of Alzheimer's disease subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Cortexyme Inc.